Description
Rolapitant, also known as SCH-619734, is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist with potential antiemetic activity. Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and late-phase CINV during the first 120 hours post-chemotherapy